## General description

<table>
<thead>
<tr>
<th>INN</th>
<th>Methotrexate</th>
</tr>
</thead>
<tbody>
<tr>
<td>ATC codes</td>
<td>L01BA01 L04AX03</td>
</tr>
<tr>
<td>Medicine type</td>
<td>Chemical agent</td>
</tr>
</tbody>
</table>

### EML status history
- First added in 1977 ([TRS 615](https://wwwebrecht.org/)) for Unspecified malignant neoplasms of ill-defined or unspecified sites
- Added in 1997 ([TRS 882](https://wwwebrecht.org/)) for Rheumatoid arthritis, serology unspecified
- Added in 2011 ([TRS 965](https://wwwebrecht.org/)) for Juvenile idiopathic arthritis
- Added in 2015 ([TRS 994](https://wwwebrecht.org/)) for Malignant neoplasms of breast
- Added in 2015 ([TRS 994](https://wwwebrecht.org/)) for Malignant trophoblastic neoplasms of placenta
- Added in 2015 ([TRS 994](https://wwwebrecht.org/)) for Osteosarcoma of bone and articular cartilage of unspecified sites
- Added in 2015 ([TRS 994](https://wwwebrecht.org/)) for Lymphoid leukaemia, not elsewhere classified
- Added in 2015 ([TRS 994](https://wwwebrecht.org/)) for Acute myeloid leukaemia with recurrent genetic abnormalities
- Removed in 2015 ([TRS 994](https://wwwebrecht.org/)) for Unspecified malignant neoplasms of ill-defined or unspecified sites
- Added in 2021 ([TRS 1035](https://wwwebrecht.org/)) for Burkitt lymphoma including Burkitt leukaemia
- Added in 2023 ([TRS 1049](https://wwwebrecht.org/)) for Anaplastic large cell lymphoma, ALK-positive
- Added in 2023 ([TRS 1049](https://wwwebrecht.org/)) for Anaplastic large cell lymphoma, ALK-negative
- Added in 2023 ([TRS 1049](https://wwwebrecht.org/)) for Langerhans cell histiocytosis
- Added in 2023 ([TRS 1049](https://wwwebrecht.org/)) for Psoriasis of unspecified type
- Application rejected in 2023 ([TRS 1049](https://wwwebrecht.org/)) for Crohn disease site
- Application rejected in 2023 ([TRS 1049](https://wwwebrecht.org/)) for Psoriatic arthritis

### Recommendations

<table>
<thead>
<tr>
<th>Wikipedia</th>
<th>Methotrexate [🔗]</th>
</tr>
</thead>
<tbody>
<tr>
<td>DrugBank</td>
<td>Methotrexate [🔗]</td>
</tr>
</tbody>
</table>
**Cytotoxic medicines**

Parenteral > General injections > IV: 50 mg in vial (as sodium salt); 50 mg per 2 mL; 1000 mg per 10 mL concentrated injection
Oral > Solid: 2.5 mg (as sodium salt)
Parenteral > General injections > IV: 50 mg in vial (as sodium salt)

**Indications**

- Malignant neoplasms of breast
- Malignant trophoblastic neoplasms of placenta
- Osteosarcoma of bone and articular cartilage of unspecified sites
- Lymphoid leukaemia, not elsewhere classified
- Acute myeloid leukaemia with recurrent genetic abnormalities
- Unspecified malignant neoplasms of ill-defined or unspecified sites
- Burkitt lymphoma including Burkitt leukaemia
- Anaplastic large cell lymphoma, ALK-positive
- Anaplastic large cell lymphoma, ALK-negative
- Langerhans cell histiocytosis

**Disease-modifying anti-rheumatic drugs (DMARDs)**

Oral > Solid > tablet: 2.5 mg (as sodium salt)

**Indications**

- Rheumatoid arthritis, serology unspecified

**Medicines for juvenile joint diseases**

Oral > Solid > tablet: 2.5 mg (as sodium salt)

**Indications**

- Juvenile idiopathic arthritis
Dermatological medicines > Medicines affecting skin differentiation and proliferation

Oral > Solid > tablet: 2.5 mg (as sodium salt); 10 mg (as sodium salt)

Indications

Psoriasis of unspecified type

Immunomodulators for non-malignant disease

Parenteral > General injections > SC: pre-filled syringe in multiple strengths

Indications

Crohn disease site  Psoriatic arthritis